This week in #ScienceNews and #Innovation, a study in Stem Cell Reports shows promising evidence for the use of stem cell replacement therapies in treating blindness caused by macular degeneration.
(Image Credit: Xinyi Su)
And, as countries launch their vaccination programs, one question keeps reappearing: does the length of time between COVID-19 doses really matter? Some data supports that partial immunity could spur new COVID-19 variants…read about the conundrum here.
(Image Credit: JACOB KING/PA WIRE/BLOOMBERG VIA GETTY IMAGES)
Finally, Cognito Therapeutic’s GammaSense stimulation system has received FDA breakthrough status, based on early clinical data from human trials. The system uses daily digital light and sound therapy to improve Alzheimer’s Disease phenotypes including a reduction of amyloid plaques.